Evidence map›Paper›PMID 33235919›Full record

ArticleMolecular & cellular oncology2020

RSK2 and ERα comrades-in-arms in homeostasis and transformation.

Katarzyna A Ludwik, Deborah A Lannigan

Open access · bronzeAbstract read
In one paragraph

Article in Molecular & cellular oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Katarzyna A LudwikPathology, Microbiology & Immunology, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN, USA.
Deborah A LanniganPathology, Microbiology & Immunology, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN, USA.ORCID https://orcid.org/0000-0001-8380-9240
Vanderbilt University · USVanderbilt University Medical Center · US

Funding

RSK2 in Estrogen Receptor Positive (ER+) Breast CancerR01CA213201 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LANNIGAN, DEBORAH, SULIKOWSKI, GARY ALLEN · 2018 to 2022
$1.8M
Estrogen Receptor HomeostasisR01DK113423 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LANNIGAN, DEBORAH · 2018 to 2022
$1.6M
NCI NIH HHS R01 CA213201NIDDK NIH HHS R01 DK113423
6 · The paper itself

Abstract

The physiological response to estrogen differs according to the developmental stage. We show, in the adult, estrogen-responsiveness is driven by ERK1/2 (extracellular signal-regulated kinase 1/2) whereas its downstream effector, RSK2 (p90 ribosomal S6 kinase 2), prevents continuous ERK1/2 activity through regulation of oxidative stress. Bioinformatic analysis revealed RSK2 association with breast cancer risk and oral contraceptives.

Indexed as

breast cancerERK1/2Estrogenestrous cycleexogenous estrogensoral contraceptivesp90 ribosomal S6 kinasep90RSK2RSK2

Identifiers

PMID33235919
PMCPMC7671069
OpenAlexW3096201272

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.